INTRODUCTION
The bactericidal action of moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. Difluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. This combination of drugs will be used to treat optical infections.
The literature is enriched with several methods for determination of MOX and DIFLU in pharmaceutical dosage forms either as a single drug or in combination with some other drugs. The most extensively used technique for estimation of MOX are by UV [3] [4] [5] [6] , HPLC [7] [8] [9] [10] [11] [12] [13] [14] , and UPLC 15 methods and most extensively used technique for estimation of DIFLU is by HPLC 16 . The aim of study is development and Validation of Analytical HPLC method for Simultaneous Estimation of Moxifloxacin and Difluprednate in their combimed Dosage form.
The present study was designed to develop a simple, precise, and rapid analytical RP-HPLC procedure, which can be used for the analysis of assay method for simultaneous estimation of Moxifloxacin and Difluprednate as there was only individual methods reported for both drugs. The combination of these two drugs is not official in any pharmacopoeia; hence no official method is available for the simultaneous estimation of these two drugs in their combined dosage forms. Literature survey of Moxifloxacin and Difluprednate revealed several methods for detecting these drugs individually but there is no method for their simultaneous estimation using RP-HPLC. 
MATERIAL AND METHODS

Apparatus and Instrument
The analysis was carried out on a HPLC system (Shimadzu LC-20-AT) equipped with UV detector. Other apparatus and instruments used were a micro analytical balance (Shimadzu), Ultrasonic Cleaner (EIE Instruments Pvt. Ltd. Ahmedabad), Nylon Membrane Filters (0.22mcm, 47 mm D). All instruments and glass wares were calibrated.
Reagents and Materials
Moxifloxacin and Difluprednate were obtained as gratis sample from Accurate Pharmaceuticals, Godhra. Methanol HPLC Grade, Water HPLC Grade, Phosphate Buffer , O-Phosphoric Acid were used which were obtained from Samir Tech-Chem Pvt. Ltd. A stockstandard solution of MOX and DIFLU was prepared by dissolving accurately weighed amount of pure drug in mobie phase.
Mobile Phase:
Phosphate Buffer (pH 3.5) : Methanol(35:65 v/v). The mobile phase was filtered through Millipore filter paper type HV (0.45 µm) and degassed by sonication.
Chromatographic conditions
Chromatographic analysis was carried out on an an inertsil C-18 column, (5 µm, 250mm x 4.6mm i.d) LC-20 AT. The mobile phase consisted of Phosphate Buffer(pH 3.5) : Methanol(35:65 v/v). The mobile phase was filtered through Millipore filter paper type HV (0.45 µm) and degassed by sonication, was pumped at 1.0 ml/min flow rate. The column was thermostated at room temperature. Under these conditions the runtime was 10 min.
Preparation of standard stock solution of MOX (500 μg/ml) and DIFLU (50μg/ml)
A 50 mg of standard MOX and 5 mg of standard DIFLU was weighed and transferred to a 100 ml volumetric flask each and dissolved in 25 ml mobile phase. The flask was shaken and volume was made up to the mark with mobile phase to give a solution containing 500 μg/ml MOX and 50 μg/ml of DIFLU.
Preparation of combined working standard solution containing MOX and DIFLU in ratio of 10:1
Accurately weighed 50 mg MOX and 5 mg of DIFLU were transferred to 100 ml volumetric flask, dissolved in sufficient amount of mobile phase and diluted up to mark with mobile phase to get concentration of 500 μg/ml MOX and 50 μg/ml DIFLU. This solution was diluted further to get the concentrations in range of 25, 37.5, 50, 62.5, 75 μg/ml Moxifloxacin and 2.5, 3.75, 5.0, 6.25, 7.5 μg/ml Difluprednate.
Method Validation
Precision
Repeatability: Precision of the method was studied by making repeated injections of the mixture of drugs on the same day for intraday precision.The %RSD after six determinations was determined at 50 µg/ml for MOX and 5 µg/ml for DIFLU.
Intraday and Interday Precision:
Intraday and Interday precision for method were measured in term of %RSD. The experiment was repeated three times in a day for intraday and on three different days for interday precision by taking small, middle and higher concentration of MOX(25, 50, 75 µg/ml) and DIFLU(2.5, 5.0, 7.5 µg/ml).
Linearity:
The linearity of measurement was evaluated by analyzing standard solutions of MOX and DIFLU in the range of 25-75 µg/ml and 2.5-7.5 µg/ml for both drugs respectively and calibration plot was constructed.
Limit of Detection (LOD) and Limit of Quantitation (LOQ):
LOD and LOQ of MOX and DIFLU were determined by calibration curve method. Solutions of Moxifloxacin and Difluprednate were prepared in the range of 25-75 µg/ml and 2.5-7.5 µg/ml for both drugs respectively and injected in triplicate.
Accuracy:
Accuracy of the method was calculated by recovery studies at three levels by standard addition method, which is, spiking about 80%, 100%, 120% of MOX and DIFLU to the standard solutions containing 25 µg/ml of MOX and 2.5 µg/ml of DIFLU.
Robustness:
Influence of small changes in chromatographic conditions such as change in flow rate, that is, ±0.2 ml/min, mobile phase composition ±2 ml and pH ±0.2 was studied to determine the robustness of the method for the development of RP-HPLC method for the simultaneous estimation of MOX and DIFLU and their %RSD was determined.
System Suitability:
The stock solution containing 50 µg/ml of MOX and 5 µg/ml of DIFLU was injected and repeated five times and the chromatograms were recorded.The resolution, number of theoretical plates, and peak asymmetry were calculated to determine whether the result complies with the recommended limit.
RESULTS AND DISCUSSION
FIGURE 3: Chromatogram of MOX and DIFLU respectively
Optimization of Chromatographic conditions
To optimize the chromatographic conditions for separation of Moxifloxacin and Difluprednate, mobile phase composition, the effect of temperature and wavelength of detection investigated.
During the method development work, enable C18 column (25 cm× 4.6 mm i.d.) with particle size of 5 µm was used and gave the suitable resolution. The mobile phase composition was prepared with appropriate proportion of phosphate buffer (Ph 3. It was shown that the most efficient resolution and peak symmetry for Moxifloxacin and Difluprednate with a mobile phase composed of phosphate buffer (Ph 3.5) :
Methanol (35:65 v/v) and a flow rate of 1 ml/min. The retention time for Moxifloxacin and Difluprednate were found to be 3.99 and 6.637 min respectively.
The wavelength selected was from the overlay of Moxifloxacin and Difluprednate. Both the drugs showed typical peak nature and peaks were symmetrical at 244 nm. Hence the wavelength has been selected as the detection wavelength.
Validation
Linearity and Range
The linearity of measurement was evaluated by analyzing standard solutions of MOX and DIFLU in the range of 25-75 µg/ml and 2.5-7.5 µg/ml respectively for both drugs and calibration plot was constructed. 
Precision
Precision of the method was studied by making repeated injections of the mixture of drugs. The Relative Standard Deviation (%RSD) after six determinations was 0.67% at 50 μg/ml for MOX and 1.23% at 5 μg/ml for DIFLU (see Table 2 ). 
LOD and LOQ
LOD and LOQ of MOX and DIFLU were determined by calibration curve method. Solutions of MOX and DIFLU were prepared in the range of 25-75 μg/ml and 2.5-7.5 μg/ml respectively and injected in triplicate (see Table  1 ).
Accuracy
Accuracy of the method was calculated by recovery studies at three levels by standard addition method. The mean percentage recoveries obtained for MOX and DIFLU were 99.59% and 99.72%, respectively (see Table 3 ). 
Robustness
The method for the development of RP-HPLC method for the simultaneous estimation of MOX and DIFLU was found to be robust as the % RSD was found to be less than 2 (see Table 4 ) 
System Suitability
The resolution, number of theoretical plates, and peak asymmetry were calculated for the standard solutions.
The stock solution containing 50 μg/ml of MOX and 5 μg/ml of DIFLU was injected and repeated five times and the chromatograms were recorded. The resolution, number of theoretical plates, and peak asymmetry were calculated to determine whether the result complies with the recommended limit (see Table 5 ) 
Preperation of sample solution:
DIFLUMOX eye drops containing 5 % of MOX and 0.5 % of DIFLU is available in local market which is marketed by Ajanta Pharma(Mumbai). It contains 50 mg of MOX and 5 mg of DIFLU per ml. For preparation of stock solution, 1 ml from the suspension was taken in 10 ml volumetric flask and diluted up to 10 ml with mobile phase. Then it was filtered through whatman filter paper (0.45μ). It was concentration of 5000 μg/ml of MOX and 500 μg/ml of DIFLU. From that 1 ml of aliquots was taken and diluted up to 10 ml for getting concentration of 500 μg/ml of MOX and 50 μg/ml of DIFLU. From this stock solution, working standard solution of 50 μg/ml of MOX and 5 μg/ml of DIFLU was prepared by taking 1 ml and diluted it up to 10 ml with mobile phase. This solution was used for the estimation of MOX and DIFLU in their combined dosage form. 
CONCLUSION
The proposed RP-HPLC method was used for the simultaneous estimation of Moxifloxacin and Difluprednate was found to be sensitive, accurate, precise, simple, and rapid. Hence the present RP-HPLC method may be used for routine analysis of the raw materials as well as combined dosage formulations containing Moxifloxacin and Difluprednate.
